甲状腺乳头状癌BRAF V600E基因突变与临床及超声特征的相关性研究  

Association Between BRAF V600E Mutation and the Clinical and UltrasonographicFeatures in Papillary Thyroid Carcinoma

作　　者：王国涛 黎燕[2] 梁瑾瑜[1] 张晓儿 刘保娴 谢晓燕[1] Wang Guotao;Li Yan;Liang Jinyu;Zhang Xiaoer;Liu Baoxian;Xie Xiaoyan(Departmient of Ultrasound,the First Afiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong 510080,China;Department of Pathoglogy,the First Afiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong 510080,China)

机构地区：[1]中山大学第一附属医院超声医学科,广州市510080 [2]中山大学第一附属医院病理科,广州市510080

出　　处：《中国超声医学杂志》2021年第4期376-379,共4页Chinese Journal of Ultrasound in Medicine

基　　金：广东省自然科学基金(No.2017A030310205);国家自然科学基金(No.81701708)。

摘　　要：目的探讨甲状腺乳头状癌(PTC)BRAF V600E基因突变与临床及超声特征的相关性。方法回顾性分析术后证实为PTC的82例患者,共96个结节的临床及超声特征。分析PTC的BRAF V600E基因突变与临床、超声特征包括2017年ACR甲状腺影像报告和数据系统(TI-RADS)之间的关系。结果 96个PTC中,突变率74.0%(71/96)。单因素结果显示,TPO-Ab、中央区颈部淋巴结转移、PTC结节的形态和边缘的差别有统计学意义(P=0.008~0.041)。这4个因素和年龄(P=0.084<0.1)纳入多因素Logistic回归分析,其结果显示,TPO-Ab、中央区颈部淋巴结转移、PTC结节的形态为BRAF V600E基因突变的独立预测因素(P=0.018~0.030)。结论 TPO-Ab、中央区颈部淋巴结转移、PTC结节的形态能预测PTC BRAF V600E基因突变。对于临床及超声特征可疑的PTC,术前临床检查及超声评估对治疗决策有一定的指导意义。Objective To explore the association between BRAF V600 E mutation and the clinical and ultrasonographic features in papillary thyroid carcinoma(PTC). Methods 82 patients with 96 surgically confirmed PTCs were included in this retrospective study. The relationship between BRAF V600 E mutation of PTC and the clinical and ultrasonographic characteristics including the 2017 ACR Thyroid Imaging, Reporting and Data System(TI-RADS) were analyzed. Results The BRAF V600 E mutation rate was 74.0%(71 of 96). In the univariate analysis, TPO-Ab, the central lymph node metastasis(CLNM), and the morphology, margine of nodules were significantly different between BRAF(+) and BRAF(-) groups(P=0.008-0.041). These 4 factors and age(P=0.084<0.1) were included in multivariate logistic regression analysis. The results showed that TPO-Ab, CLNM, and the morphology of nodules were independent predictors of BRAF V600 E gene mutation.(P=0.018-0.030).Conclusions TPO-Ab, CLNM, and the morphology of nodules can predict PTC BRAF V600 E mutation. For PTC with suspicious clinical and ultrasound characteristics, preoperative clinical examination and ultrasound evaluation have certain guiding significance for treatment decision.

关 键 词：甲状腺乳头状癌 BRAF V600E基因突变 超声特征 甲状腺影像报告和数据系统 

分 类 号：R736.1[医药卫生—肿瘤]